Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO · NASDAQ Global Market
-$0.05 today
Vol 1.08M · Avg 0.86M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$100.0M -1.7% | -$98.3M -48.1% | -$66.4M -12.0% | -$59.3M -17.1% | -$50.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $379.0K -81.1% | $2.0M +8.6% | $1.8M +61.0% | $1.1M +8707.7% | $13.0K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $12.1M -2.7% | $12.5M +309.9% | $3.0M +70.9% | $1.8M +361.4% | $386.0K | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$9.5M -448.7% | $2.7M +84.1% | $1.5M -17.3% | $1.8M -70.4% | $6.0M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$1.6M -165.6% | $2.4M +1421.1% | -$180.0K +57.7% | -$426.0K -114.1% | $3.0M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$8.0M -2366.1% | $351.0K -78.9% | $1.7M -25.0% | $2.2M -26.7% | $3.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$1.6M -6839.4% | -$23.0K -104.3% | $530.0K | $0 | $0 | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$98.6M -21.5% | -$81.2M -36.4% | -$59.5M -9.0% | -$54.6M -23.5% | -$44.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$397.0K +17.5% | -$481.0K -191.5% | -$165.0K +81.7% | -$901.0K -379.3% | -$188.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$195.4M -108.8% | -$93.6M | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $105.5M | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $17.0K | $0 +100.0% | -$50.0K +78.2% | -$229.0K | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$90.3M +4.1% | -$94.1M -56916.4% | -$165.0K +81.7% | -$901.0K -379.3% | -$188.0K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$533.0K -30.0% | -$410.0K -111.5% | $3.6M +2293.3% | -$163.0K | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $217.3M +145.0% | $88.7M -11.5% | $100.3M +30096.1% | $332.0K +95.3% | $170.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 +100.0% | -$17.0K | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $491.0K +1502.9% | -$35.0K -110.5% | $332.0K +263.5% | -$203.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $216.8M +144.2% | $88.8M -14.5% | $103.8M +54815.9% | $189.0K -99.9% | $150.9M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $28.0M +132.4% | -$86.5M -295.9% | $44.1M +179.8% | -$55.3M -151.9% | $106.5M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$99.0M -21.2% | -$81.6M -36.8% | -$59.7M -7.6% | -$55.5M -25.0% | -$44.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.29B
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$438.92M
DBV Technologies S.A.
NASDAQ:DBVT
$385.73M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$347.71M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$346.08M
Amarin Corporation plc
NASDAQ:AMRN
$334.13M
Silence Therapeutics plc
NASDAQ:SLN
$324.26M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$299.95M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.26M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.90M
SEC Filings
Recent regulatory filings
No filings found.
Does LXEO generate free cash flow?
Lexeo Therapeutics, Inc. Common Stock (LXEO) generated -$98,958,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does LXEO produce?
Operating cash flow was -$98,561,000.00, before capital expenditures of $397,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.